Last Updated: November 16, 2026

MACI Drug Profile

« Back to Dashboard


Summary for Tradename: MACI
High Confidence Patents:5
Applicants:1
BLAs:1
Pharmacology for MACI
Established Pharmacologic ClassAutologous Cultured Cell
Chemical StructureChondrocytes
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for MACI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for MACI Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Vericel Corporation MACI autologous cultured chondrocytes on porcine collagen membrane Cell Sheets 125603 ⤷  Start Trial 2033-11-25 DrugPatentWatch analysis and company disclosures
Vericel Corporation MACI autologous cultured chondrocytes on porcine collagen membrane Cell Sheets 125603 ⤷  Start Trial 2019-01-13 DrugPatentWatch analysis and company disclosures
Vericel Corporation MACI autologous cultured chondrocytes on porcine collagen membrane Cell Sheets 125603 ⤷  Start Trial 2028-04-04 DrugPatentWatch analysis and company disclosures
Vericel Corporation MACI autologous cultured chondrocytes on porcine collagen membrane Cell Sheets 125603 ⤷  Start Trial 2028-11-06 DrugPatentWatch analysis and company disclosures
Vericel Corporation MACI autologous cultured chondrocytes on porcine collagen membrane Cell Sheets 125603 ⤷  Start Trial 2032-06-08 DrugPatentWatch analysis and company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for MACI Derived from Patent Text Search

These patents were obtained by searching patent claims

MACI Market Dynamics, Financial Trajectory, Patent Protection, and Generic Entry Risk

Last updated: November 9, 2026

MACI is Vericel’s commercial autologous cell-therapy product for repairing symptomatic full-thickness cartilage defects of the knee. Its market position rests on FDA approval, surgeon adoption, reimbursement, manufacturing capacity, and a specialized two-stage treatment pathway rather than on conventional small-molecule patent protection. MACI is Vericel’s largest revenue product and the main driver of its long-term growth profile.

What is MACI and how does the FDA regulate it?

MACI, or autologous cultured chondrocytes on porcine collagen membrane, is manufactured from a patient’s own cartilage cells. The product is indicated for adults aged 18 to 55 with symptomatic, single or multiple full-thickness cartilage defects of the knee measuring 3 to 10 cm².[1]

Regulatory attribute MACI status
Sponsor Vericel Corporation
FDA application Biologics License Application 125684
FDA approval December 13, 2016
Product type Autologous cultured chondrocyte-cell therapy
Delivery system Implantable porcine type I/III collagen membrane
Indication Symptomatic full-thickness cartilage defects of the knee
Patient age Adults 18 to 55
Treatment model Two-stage procedure
Manufacturing model Patient-specific, centralized manufacturing
FDA exclusivity 12-year reference-product exclusivity under the BPCIA, subject to statutory interpretation and applicable extensions
Orange Book status Not listed as a conventional small-molecule drug product

MACI requires an initial arthroscopic biopsy, shipment of the tissue to Vericel, cell expansion and seeding onto the collagen membrane, and a later implantation procedure. The process creates operational barriers that are more important commercially than the price of the implant alone.

How large is the MACI market?

The addressable market is the population of patients with focal cartilage defects who are young or middle-aged, symptomatic, and appropriate for cartilage restoration rather than total knee replacement or routine arthroscopy.

The market is constrained by diagnosis and treatment selection. Many patients with knee pain have osteoarthritis, diffuse cartilage loss, meniscal disease, obesity-related joint stress, or malalignment. MACI is designed for focal defects, which makes the clinically eligible population smaller than the broader knee-pain market.

What drives MACI adoption?

The principal demand drivers are:

  1. Increasing use of cartilage-restoration procedures among younger active patients.
  2. Avoidance or postponement of knee arthroplasty.
  3. Greater surgeon familiarity with matrix-induced autologous chondrocyte implantation.
  4. Improved reimbursement coverage and coding clarity.
  5. Vericel’s orthopedic sales force and surgeon-training infrastructure.
  6. Clinical evidence supporting durability and functional improvement in appropriate patients.

The principal constraints are the two-stage procedure, the need for specialized orthopedic surgeons, patient screening, operating-room scheduling, manufacturing lead times, and payer authorization.

MACI competes with osteochondral autograft transfer, osteochondral allograft transplantation, microfracture, bone marrow stimulation, and other cartilage-repair techniques. These alternatives are not direct generic substitutes because they differ in patient selection, surgical technique, reimbursement, and clinical durability.

What is the financial trajectory of MACI and Vericel?

MACI has been Vericel’s primary growth product since its 2016 approval. Vericel reports revenue by product, with MACI accounting for the majority of company sales and Epicel providing the remainder of the commercial base.[2]

Period Vericel financial direction MACI financial direction
2016-2018 Commercial launch and infrastructure buildout Early adoption from a small base
2019-2020 Revenue expanded despite COVID-19 procedure disruption Continued procedure-volume growth, with temporary pandemic pressure
2021-2022 Recovery in elective orthopedic procedures Stronger case volumes and broader surgeon adoption
2023 Company revenue reached more than $200 million MACI remained the dominant revenue contributor
2024 outlook Continued double-digit commercial growth targeted by management Growth dependent on procedure volume, capacity, reimbursement, and sales execution

Vericel’s annual reports show a transition from a development-stage cell-therapy company to a commercial specialty-biologics business. MACI revenue growth has generally been driven by procedure volume rather than by broad population expansion.

What is MACI’s revenue exposure for Vericel?

MACI represents the majority of Vericel’s product revenue. Epicel, an autologous cultured epidermal-cell product for severe burns, provides a second revenue stream but has a smaller and more specialized market.

This concentration creates two opposing effects:

  • MACI gives Vericel a clear growth engine with a large orthopedic commercial opportunity.
  • The company remains exposed to orthopedic procedure volumes, reimbursement changes, manufacturing interruptions, and surgeon adoption rates.

Vericel does not disclose MACI gross profit in the same detail as total-company results. Profitability depends on manufacturing utilization, batch success, labor, logistics, sales expenses, patient acquisition, and the cost of maintaining specialized facilities.

When does MACI lose regulatory exclusivity?

MACI received FDA approval in December 2016. Under the Biologics Price Competition and Innovation Act, a reference biological product generally receives 12 years of reference-product exclusivity from first licensure. On that basis, the core U.S. reference-product exclusivity period would run into December 2028, before considering any applicable statutory adjustments.[3]

Regulatory exclusivity does not equal patent expiration. A competitor could face:

  • FDA reference-product exclusivity;
  • patent claims covering manufacturing, cell expansion, scaffolds, or methods of use;
  • clinical and technical requirements for a biosimilar or competing cell therapy;
  • facility and chain-of-identity requirements;
  • physician and payer adoption barriers.

MACI’s regulatory protection is therefore likely to remain commercially meaningful after the earliest patent expiration date, especially because a patient-specific autologous product is difficult to reproduce through a conventional generic pathway.

What patents protect MACI?

MACI does not fit the standard Orange Book patent model used for tablets, capsules, and injectable small molecules. The product is licensed under a BLA, and biological-product patent information is not presented through the same Orange Book framework used for approved small-molecule drugs.

The relevant intellectual-property categories include:

Protection category Commercial relevance
Cell-expansion methods Protects culture conditions and production workflows
Chondrocyte seeding methods Protects the process of applying cells to the collagen scaffold
Scaffold and membrane technology Protects the collagen carrier and cell-support structure
Manufacturing controls Protects process parameters, testing, and release specifications
Patient-specific logistics Creates operational know-how around biopsy, transport, production, and implantation
Method-of-use claims May cover repair of focal cartilage defects using cultured autologous chondrocytes
Trade secrets Can protect process details that are difficult to identify from the finished product

A complete MACI patent analysis requires claim-level review of Vericel, former Genzyme, and related assignee portfolios across the United States and other jurisdictions. Public FDA materials do not provide an Orange Book-style definitive list of MACI patents.

The practical patent position is stronger than a single composition-of-matter patent would suggest because a competitor must reproduce the treatment workflow, demonstrate product consistency, establish a compliant manufacturing process, and obtain regulatory approval.

How strong is the MACI patent and regulatory estate?

MACI has a moderate-to-strong commercial protection profile, but its strength comes from several layers rather than a single blocking patent.

Strong protection factors

  • FDA approval for a defined cartilage-repair indication.
  • Twelve-year reference-product exclusivity under the BPCIA framework.
  • Patient-specific manufacturing.
  • Specialized cell-processing equipment and quality systems.
  • Clinical and physician adoption barriers.
  • Proprietary know-how in cell expansion and product release.
  • High switching costs for surgeons and treatment centers.

Weaknesses and limitations

  • Autologous cell therapy does not necessarily support broad composition-of-matter claims.
  • Patent terms may expire at different times.
  • Competitors could pursue distinct scaffolds or cell-processing approaches.
  • Osteochondral grafts and other procedures do not need to copy MACI.
  • A competing allogeneic cartilage product could target the same clinical market through a different regulatory route.
  • Regulatory exclusivity eventually expires, even if manufacturing complexity remains.

The most credible long-term threat is not a conventional generic tablet. It is a competing cartilage-restoration platform with a simpler procedure, shorter treatment timeline, lower cost, or improved reimbursement profile.

Are there Paragraph IV challenges to MACI?

A conventional Paragraph IV challenge is unlikely to be the primary pathway for MACI because Paragraph IV litigation applies to patents listed in the FDA Orange Book for abbreviated new drug applications.

MACI is approved under a BLA rather than a standard new drug application. A future competitor would more likely pursue a biosimilar or other biologic regulatory pathway, or seek approval for a distinct cell-therapy product with its own clinical and manufacturing package.

No major publicly reported Paragraph IV litigation involving MACI is identified in the FDA approval framework or Vericel’s principal public disclosures through the available reporting period. The absence of a Paragraph IV dispute does not eliminate competitive risk. It reflects the product’s biologic and cell-therapy classification.

What biosimilar risks exist for MACI?

Biosimilar risk is lower and more complex than for a conventional recombinant protein.

A MACI follow-on product would need to address:

  • autologous cell sourcing;
  • identity and chain of custody;
  • cell expansion;
  • cellular phenotype and potency;
  • scaffold integration;
  • sterility and release testing;
  • patient-specific manufacturing;
  • surgical implantation;
  • clinical comparability.

A biosimilar applicant might attempt to demonstrate similarity to MACI, but the individualized nature of the product makes interchangeability and manufacturing comparability difficult. A competing product could instead pursue a separate BLA for an allogeneic or otherwise modified cartilage-repair therapy.

The most likely competitive sequence is:

  1. Alternative surgical technologies continue taking share in selected patients.
  2. Follow-on biologic or cell-therapy developers target differentiated products.
  3. Direct MACI biosimilar competition remains limited unless manufacturing technology changes materially.
  4. Price competition increases only after a credible alternative achieves reimbursement and surgeon adoption.

What is the MACI litigation and settlement status?

No major publicly reported U.S. patent litigation or Paragraph IV settlement has materially altered MACI’s commercial exclusivity profile through the available reporting period.

Vericel’s principal business risks have been commercial and operational rather than litigation-driven. These include product manufacturing, regulatory compliance, reimbursement, procedure volumes, facility capacity, and expansion of the orthopedic sales organization.

A settlement-driven generic-entry date is therefore not a current central assumption for MACI forecasting.

What manufacturing barriers protect MACI?

Manufacturing is one of MACI’s most important barriers to entry. Each product is linked to an individual patient, creating a chain-of-identity requirement from biopsy through implantation.

The process requires:

  • controlled receipt of patient tissue;
  • validated cell expansion;
  • seeding onto the collagen membrane;
  • testing and release;
  • temperature-controlled shipment;
  • coordination with the implantation procedure.

Unlike a conventional drug, inventory cannot be produced in advance for broad distribution. Manufacturing capacity must scale with surgical scheduling and patient enrollment. Failures in biopsy quality, cell expansion, sterility, logistics, or implantation timing can affect both revenue and patient outcomes.

Vericel’s investment in manufacturing infrastructure has strategic value because it supports regulatory compliance and makes rapid competitive entry more difficult. Capacity expansion can also improve fixed-cost absorption and gross-margin performance if procedure volumes continue to rise.

How does MACI compare with other cartilage-repair products?

Treatment Product model Procedure profile Main competitive issue
MACI Autologous chondrocytes on collagen membrane Two-stage Manufacturing complexity and reimbursement
Microfracture Bone-marrow stimulation Usually one-stage Lower cost but variable durability
Osteochondral autograft Patient’s own cartilage and bone Usually one-stage Donor-site limitations and defect size
Osteochondral allograft Donor tissue Usually one-stage Tissue availability and logistics
Particulated cartilage Cartilage fragments or graft material Often one-stage Variable evidence and product standardization
Knee arthroplasty Joint replacement Major surgery Usually aimed at more advanced disease

MACI’s commercial opportunity is largest where surgeons want a biological repair option for focal defects and where patients are too young or clinically inappropriate for arthroplasty.

What generic launch scenarios exist for MACI?

Scenario 1: No direct follow-on before the late 2020s

This is the most favorable scenario for Vericel. MACI maintains regulatory and operational exclusivity while procedure volumes expand.

Scenario 2: Alternative cell therapy launches after 2028

A competitor could pursue a differentiated BLA rather than a biosimilar pathway. Market entry would depend on clinical evidence, manufacturing scale, reimbursement, and surgeon confidence.

Scenario 3: Surgical substitutes take share

Osteochondral allografts, autografts, microfracture, or new scaffold technologies could reduce MACI utilization without infringing MACI patents or requiring a direct regulatory challenge.

Scenario 4: Reimbursement pressure

Payers could limit coverage, impose prior authorization, or favor lower-cost procedures. This scenario would affect revenue before patent or regulatory exclusivity ends.

Which companies are challenging MACI?

No company has established a direct, FDA-approved U.S. commercial substitute that matches MACI’s product and indication through the available reporting period.

The competitive field includes:

  • orthopedic companies selling grafting systems;
  • tissue banks supplying osteochondral allografts;
  • developers of cartilage scaffolds;
  • regenerative-medicine companies developing cell therapies;
  • hospitals and surgeons using microfracture or autograft procedures.

Competition is therefore fragmented. MACI’s principal threat is market substitution rather than an immediate generic launch.

What is the geographic coverage of MACI?

MACI’s commercial value is primarily tied to the United States, where Vericel has FDA approval, a direct sales organization, reimbursement infrastructure, and centralized manufacturing.

International expansion would require:

  • country-specific regulatory approval;
  • local reimbursement;
  • manufacturing or import controls;
  • patient-tissue logistics;
  • surgeon training;
  • compliance with cell and tissue regulations.

Because MACI is patient-specific, international expansion is more difficult than exporting a conventional pharmaceutical product. Geographic growth could require regional manufacturing or highly reliable cross-border logistics.

Key Takeaways

  • MACI is Vericel’s principal growth product and the largest contributor to company revenue.
  • FDA approval occurred in December 2016 for symptomatic full-thickness knee cartilage defects in adults aged 18 to 55.
  • The 12-year BPCIA reference-product exclusivity period points to late 2028 as the core U.S. regulatory exclusivity milestone.
  • MACI is not a conventional Orange Book product, and Paragraph IV litigation is not the expected primary challenge route.
  • Its protection comes from regulatory exclusivity, manufacturing know-how, patient-specific logistics, clinical evidence, and surgeon adoption.
  • Direct biosimilar competition is difficult because the product is autologous and individualized.
  • The major near-term risks are reimbursement, procedure volume, manufacturing capacity, and alternative cartilage-repair procedures.
  • The company’s long-term revenue trajectory depends on expanding MACI utilization while maintaining Epicel as a second commercial base.

FAQs

Is MACI a drug or a medical device?

MACI is an FDA-licensed biological product and cell therapy delivered on a collagen membrane. It is not regulated as a conventional small-molecule drug or standalone orthopedic device.

Does MACI have a patent listed in the Orange Book?

MACI is approved under a BLA and is not treated like a conventional Orange Book small-molecule product. Relevant protection may involve patents, regulatory exclusivity, manufacturing know-how, and method-of-use rights.

Can a generic company copy MACI?

A conventional generic cannot simply copy MACI through an abbreviated new drug application. A competing company would likely need a biologic or cell-therapy regulatory strategy and would face complex patient-specific manufacturing requirements.

What is the biggest commercial threat to MACI?

The largest commercial threat is substitution by other cartilage-repair procedures or a new regenerative product with a simpler one-stage procedure, lower cost, or better payer coverage.

Is MACI revenue recurring?

MACI revenue is procedure-driven rather than subscription-based. Repeat revenue depends on new eligible patients, surgeon utilization, reimbursement, and the expansion of cartilage-restoration procedures.

References

  1. U.S. Food and Drug Administration. (2016). MACI prescribing information. https://www.accessdata.fda.gov
  2. Vericel Corporation. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission. https://www.sec.gov
  3. U.S. Food and Drug Administration. (2023). Regulatory considerations for demonstrating biosimilarity to a reference product. https://www.fda.gov
  4. Vericel Corporation. (2024). Fourth-quarter and full-year financial results and corporate updates. https://investors.vcel.com
  5. U.S. Congress. (2010). Patient Protection and Affordable Care Act, Title VII: Improving access to innovative medical therapies. Pub. L. No. 111-148.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.